

The Future of Artificial Intelligence in Gene Therapy

Pragnyasri Sankar

Research Scholars Program, Harvard Student Agencies in collaboration with Learn with Leaders

ABSTRACT

This research paper examines the integration of CRISPR-Cas9 gene editing technology with Artificial Intelligence (AI) in the realm of precision cancer medicine. CRISPR-Cas9, a breakthrough in molecular biology, enables targeted DNA modifications within genomes, revolutionizing therapeutic interventions. However, its efficacy is challenged by off-target effects, necessitating enhanced accuracy and efficiency. Through qualitative, secondary research, this study analyzes existing literature to understand AI's role in advancing gene therapy. It highlights CRISPR-Cas9's applications in cancer heterogeneity, drug target identification, and biomarker discovery. The paper also explores the evolution of CRISPR-Cas9 and its implications in precision medicine and antiviral research. A significant focus is placed on machine learning and deep learning algorithms to refine guide RNA design, crucial for reducing off-target effects and improving gene editing specificity. The paper concludes that the synergy of CRISPR-Cas9 and AI offers promising avenues for cancer research, therapy, and understanding complex diseases.

Keywords: CRISPR-Cas9, Precision Medicine, Artificial Intelligence, Gene Editing, Cancer Research, Machine Learning.

INTRODUCTION

Gene editing represents a significant leap forward in molecular biology, ushering in a new era of unprecedented precision in manipulating genetic sequences. A particularly notable advancement in this field is CRISPR-Cas9, or Clustered Regularly Interspaced Short Palindromic Repeats and CRISPR-associated protein 9. This technology enables the selective and rapid modification of DNA within a genome—the complete set of genes or genetic material present in a cell or organism. This innovation has revolutionized various fields, ranging from functional genomics to potential therapeutic interventions.

However, despite these advantages, a persistent challenge remains. The CRISPR-Cas9 process can lead to off-target effects, potentially introducing unintended genetic alterations. Addressing this issue is crucial, particularly in therapeutic contexts where precision is of utmost importance. Ongoing research aims to enhance the accuracy of gene editing while maintaining its efficiency, a critical endeavor in the advancement of gene therapy.




Figure 1

In Figure 1, panel A depicts the initiation and progression of cancer, resulting from a combination of various genetic and epigenetic alterations. Panel B illustrates the diverse mechanisms contributing to cancer development. Panel C demonstrates the process by which CRISPR-Cas9 specifically edits genes or growth factors implicated in cancer.

Finally, panel D shows the numerous mutations and dysregulated gene expressions in cancer-related genes. These genes may promote tumor growth, contribute to the formation of cancer stem cells, enable cancer cells to resist treatment, or suppress tumors. Researchers utilize the CRISPR-Cas9 system to target and study these genes, aiding in the identification of new biomarkers and potential targets for cancer treatment.

Although the system can introduce precise changes at the desired target site, its ability to recognize and bind to sequences with partial homology to the target can cause off-target cleavage. This unintentional action could potentially lead to mutations, thereby compromising the safety and efficacy of genome editing applications. Consequently, enhancing the specificity of CRISPR-Cas9 has become a predominant objective in the field. This is particularly crucial when considering the clinical translation of CRISPR-Cas9 for gene therapy and precision medicine, where maintaining on-target efficacy while preventing any unintended effects is of utmost importance. In therapeutic contexts, the precise modification of a single gene can be a matter of life or death, and off-target mutations are an unacceptable risk.

Moreover, in basic research, the reliability of genome editing outcomes directly impacts our ability to elucidate gene function and uncover the molecular basis of disease.

This research paper explores the complex challenge of enhancing the specificity of CRISPR-Cas9 by integrating it with AI, focusing primarily on minimizing unwanted effects while maintaining robust on-target efficiency. The pursuit of precision in CRISPR-Cas9 is not merely an academic exercise but a critical endeavor with far-reaching implications. Achieving this goal could unlock the full potential of CRISPR-Cas9 in various domains, from treating genetic disorders to deepening our understanding of complex biological processes.

To ensure the specificity of CRISPR/Cas9, a holistic approach is necessary, encompassing the design of guide RNAs, the engineering of Cas9 proteins, the development of tools for predicting off-target effects, and rigorous experimental validation. Balancing on-target efficiency with off-target specificity has been a longstanding challenge for researchers.

Recent advancements have been made in understanding the factors contributing to off-target cleavage in CRISPR-Cas9 and in developing methods to mitigate these effects. Solutions include high-fidelity Cas9 variants, machine learning algorithms for off-target prediction, improved delivery methods, and optimized guide RNA.

Thus, this paper aims to provide an overview of the various methods and techniques developed to enhance the specificity of CRISPR-Cas9. It will discuss the application of CRISPR-Cas9 in gene engineering for cancer research and treatment, as well as its increased efficacy in these areas. By examining the successes, challenges, and prospects, this paper contributes to the ongoing efforts to combine machine learning technology and CRISPR-Cas9 with greater precision and confidence, ultimately benefiting science and medicine.

METHODOLOGY

This research paper employs a qualitative, secondary research methodology to explore the future of Artificial Intelligence (AI) in gene therapy, with a specific focus on the CRISPR/Cas9 system. This approach involves the comprehensive analysis and synthesis of existing literature, including peer-reviewed journal articles, conference proceedings, and reports from reputable research institutions. The data collection process entailed a thorough review of electronic databases such as PubMed, Scopus, and Google Scholar, using specific keywords like "CRISPR/Cas9," "AI in gene therapy," "gene editing," and "precision medicine." This method was chosen for its effectiveness in collating and interpreting a wide range of scholarly works, providing a holistic understanding of the current state and future prospects of AI in gene therapy. It allows for the integration of diverse perspectives and findings, contributing to a more nuanced and comprehensive analysis.

The qualitative nature of this methodology is particularly suited to the exploratory nature of this research, as it facilitates an in-depth understanding of complex and evolving concepts in gene therapy and AI. By analyzing qualitative data from various sources, this study aims to identify patterns, themes, and emerging trends in the field, offering insights into potential future developments and applications.

One limitation of this research is its reliance on secondary data, which may not capture the most recent advancements in the rapidly evolving fields of AI and gene therapy. Additionally, the interpretation of existing literature is subject to the inherent biases and perspectives of the original authors, which may influence the conclusions drawn in this study.

Despite these limitations, this research provides a valuable overview of the current landscape and future directions of AI in gene therapy, offering a foundation for further empirical research.

RESULTS & DISCUSSION

CRISPR/Cas9 in Context

The CRISPR/Cas9 system offers customization for exploring gene functions through genome-wide screening and plays a crucial role in the strategic design of drugs for precision cancer therapy. This section highlights the importance of CRISPR gene-editing technology in understanding cancer heterogeneity, a key factor in enabling precision medicine in oncology. The application of CRISPR technology in identifying new drug targets and biomarkers, understanding drug resistance mechanisms, and establishing cancer models is instrumental in developing precisely targeted therapeutic agents, advancing the field of precision cancer treatment.

The accompanying schematic illustrates the progression of CRISPR-Cas9 genome engineering in identifying potential targets and determining the most suitable cancer models for each specific gene mutation in patients. Utilizing CRISPR-Cas9 for knock-in, knock-out, or CRISPR Interference (CRISPRi) screening is vital for identifying and confirming new drug targets, genes associated with cancer stem cells, and tumor-suppressor genes. This process significantly contributes to the design of personalized drugs. In CRISPR-Cas9, a knock-in involves inserting a new gene into the DNA sequence, while a knock-out entails removing an existing gene to create a transgenic organism.




Figure 2

Furthermore, base editing is a potent technique for making precise DNA alterations in living organisms. It enables the specific alteration of genetic letter pairs, akin to replacing one puzzle piece with another that fits perfectly.

Tools such as cytosine and adenosine base editors facilitate specific changes from C to T or from A to G in the genetic code. These tools allow for a more rapid and efficient investigation of how genetic code alterations relate to cancer development, thereby accelerating new drug discovery. Past research in base editing has provided insights into the mechanisms of cancer-causing mutations in various cancer types. The flexibility and precision of base editing make it an essential tool for understanding genetic variations in cancer, potentially playing a significant role in advancing precision medicine for cancer treatment.

The Evolution of CRISPR/Cas9

The discovery of CRISPR was first made in the DNA sequences of *Escherichia coli* bacteria, as described in 1987 by Ishino et al. Initially, while the biological purpose of the CRISPR system was not fully understood, scientists recognized its potential for medical research applications. This primarily involved genotyping various bacterial strains, beginning with *Mycobacterium tuberculosis*, and later extending to *Streptococcus pyogenes*. A significant advancement in understanding the biological function of CRISPR loci occurred in 1995, credited to Francisco Mojica of the University of Alicante. Mojica discovered similar structures in the archaeal genome of *Haloferax mediterranei*, a type of bacteria. He proposed that CRISPRs are part of the bacterial immune system, defending against invading viruses. In the same year, two other laboratories independently made similar discoveries.

In 2007, French food scientists Rodolphe Barrangou and Philippe Horvath, working for the Danish company Danisco, achieved a groundbreaking discovery in the CRISPR field. They studied yogurt cultures of *Streptococcus thermophilus*, using Danisco's extensive bacterial strain collection to observe how bacteria developed immunity to bacteriophages by acquiring genetic spacers at the CRISPR locus. The addition of new spacers conferred immunity to specific bacteriophages, leading to one of the earliest CRISPR-related patents. Danisco began using CRISPR-based technology to "vaccinate" bacterial cultures in 2005, marking the beginning of a new era in genetic engineering. Today, CRISPR sequences are found in most archaeal genomes and nearly half of all known bacterial genomes. However, they have not been identified in eukaryotic or viral DNA sequences.

Future of CRISPR/Cas9

As medicine becomes increasingly precise, scientists are striving to develop personalized treatments tailored to individual disease risks or predicted responses. Genome editing techniques like CRISPR/Cas9 offer the potential for customized genetic modifications to tackle complex diseases. Although most CRISPR/Cas9 research is conducted in preclinical settings, such as in vitro and ex vivo studies, applying this technology in clinical environments poses significant challenges. These challenges stem from concerns about editing efficiency and off-target effects.

Off-target effects occur when Cas9 inadvertently binds to and cuts unintended genomic sites, potentially leading to abnormal gene function. However, recent strategies and approaches have been developed to mitigate these off-target effects in the CRISPR system. These include the use of cytosine or adenine base editors, the delivery of ribonucleoproteins, employing truncated g-RNAs, adopting prime editing techniques, and selecting different Cas variants. These innovations aim to minimize the unintended consequences of CRISPR-based genetic modifications.

Beyond its role in gene editing, the CRISPR/Cas9 system has also found applications in antiviral research. Amid the ongoing COVID-19 pandemic, there is an urgent need for rapid and straightforward point-of-care testing. COVID-19, with its variation in disease symptoms among individuals, is particularly suited for precision medicine approaches. The CRISPR/Cas complex can be utilized for the detection of SARS-CoV-2, the virus responsible for COVID-19, by binding to specific target regions and cleaving nearby reporter nucleic acid constructs. This process indicates the presence of viral genetic material. Furthermore, numerous studies have employed CRISPR-based diagnostic tools, particularly Cas13, a CRISPR-Cas effector protein capable of targeting RNA, for detecting SARS-CoV-2, an RNA virus.

Despite CRISPR/Cas9 being a highly effective and advanced tool, there is considerable potential for improvement, especially for large-scale genome-wide screenings. These improvements include enhancing specificity, minimizing off-target effects, and refining analytical methods. Therefore, the future of CRISPR/Cas9 in precision medicine holds promise, provided that ethical concerns related to potential adverse effects of the system are thoughtfully considered and adequately addressed.

Implementation of AI

Achieving successful gene editing with CRISPR-Cas9 heavily relies on the design of the guide RNA (gRNA). Present efforts are concentrated on refining gRNA design to enhance its precision in targeting specific genes while minimizing unintended effects. Recent studies have introduced algorithms capable of predicting the performance of a given gRNA and its potential to cause unintended changes. These tools have significantly improved the accuracy and success rate of the CRISPR system. However, the effectiveness of a gRNA is influenced by various factors, including the cellular environment, experimental conditions, the gRNA itself, and the target DNA sequence. Machine learning (ML) algorithms have been developed to address these complexities. These ML models, trained using existing data, can predict the performance of a gRNA in new scenarios. There are three primary types of ML tools: regression-based, classification-based, and ensemble-based methods, each differing in their data usage and analysis of the target DNA sequence.

Advanced ML techniques have also facilitated the use of deep learning (DL) methods, such as artificial neural networks (ANNs), for highly precise predictions in the CRISPR-Cas9 system. DL models employ multiple layers to analyze the

gRNA-DNA sequence, applying various filters and normalization steps. These layers collectively determine the accuracy of the gRNA in targeting the intended gene.

These ML and DL methods benefit from a growing global dataset of gene editing experiments, making them invaluable in predicting the effectiveness and specificity of a given gRNA in targeting desired genes.




Figure 3 illustrates the CRISPR/Cas9 deep learning architecture. This model predicts the accuracy of CRISPR/Cas9 targeting for a specific genetic sequence. It inputs a 4x23 code matrix representing a sequence of 23 genetic letters composed of four types of nucleotides. The input passes through a convolutional layer, acting as a filter to identify matching patterns between the guide RNA (sgRNA) and the target DNA. This layer uses filters of varying sizes for effective pattern recognition. The data then undergoes batch normalization to minimize internal data variations, followed by a pooling layer that filters out less critical information, retaining only key details. The output from the pooling layer is flattened into a single vector, which connects to a fully connected layer, the model's decision-making component, determining the suitability of the input sequence for the CRISPR/Cas9 system.

In addition to predicting on-target efficacy, these algorithms can also forecast off-target effects of CRISPR/Cas9. Studies have shown that off-target effects are not random and can be minimized through proper gRNA design.

CONCLUSION

The CRISPR/Cas9 system represents a revolutionary advancement in gene editing, offering significant promise in precision cancer medicine. Its efficacy in cell screens and animal studies has been instrumental in identifying potential drug targets and cancer biomarkers, paving the way for more targeted and effective cancer therapies.

CRISPR/Cas9 has enhanced our understanding of cancer, shedding light on aspects such as metastatic potential, origin, and spread. It has revealed previously undetectable changes in cancer, offering new insights into the disease. Moreover, CRISPR/Cas9 is poised to transform immuno-oncology cancer therapy, particularly in the development of next-generation CAR-T therapies. CAR-T, a form of cancer immunotherapy, utilizes genetically modified T cells to more effectively target and destroy cancer cells. CRISPR/Cas9's precision and multiplexed editing capabilities are crucial in advancing CAR-T therapies, especially for treating solid tumors.

The combination of CRISPR-based assays with single-cell multi-omics approaches has broadened the scope of applications in studying gene alterations and tumor heterogeneity. Integrating spatial transcriptomics with pooled CRISPR libraries enhances our understanding of the impact of genetic changes on interactions within the tumor microenvironment.

Machine learning (ML)-based algorithms have significantly improved the efficiency and reduced the off-target effects of the CRISPR/Cas9 system, a vital factor for its clinical applications. Species-specific CRISPR algorithms have further optimized its effectiveness across various organisms.

Despite these advancements, extensive research and carefully designed clinical trials are essential before CRISPR technology can be routinely applied in cancer treatment. Looking ahead, we anticipate that next-generation gene editing technologies will further expand the versatility of the CRISPR/Cas9 system, solidifying its role as an indispensable tool in unraveling the complexities of human diseases.

REFERENCES

- [1]. Bhat, A. A., Nisar, S., Mukherjee, S., Saha, N., Yarravarapu, N., Lone, S. N. Masoodi, T., Chauhan, R., Maacha, S., Bagga, P., Dhawan, P., Akil, A.A.-S., El-Rifai, W., Uddin, S., Reddy, R., Singh, M., Macha, M. A., & Haris, M. (2022). Integration of crispr/cas9 with artificial intelligence for improved cancer therapeutics. *Journal of Translational Medicine*, 20(1). Available at: <https://doi.org/10.1186/s12967-022-03765-1>
- [2]. Dai, X., Blancafort, P., Wang, P., Sgro, A., & Thompson, E. W. (2020). Innovative Precision Gene-Editing Tools in Personalized Cancer Medicine. *Advanced Science*, 7(12), 1902552. <https://doi.org/10.1002/advs.201902552>
- [3]. Gostimskaya, I. (2022, August 15). CRISPR–Cas9: A history of its discovery and ethical considerations of its use in genome editing. Retrieved September 15, 2023, from <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9377665/>
- [4]. Guo, C., Ma, X., Gao, F., & Guo, Y. (2023, March 9). Off-target effects in CRISPR/Cas9 gene editing. Retrieved September 17, 2023, from <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10034092/>
- [5]. Harrison, R. (2023, July 3). AI and CRISPR precisely control gene expression [Press release]. <https://www.nyu.edu/about/news-publications/news/2023/july/ai-crispr-gene-expression.html#:~:text=By%20combining%20artificial%20intelligence%20with,generation%20of%20RNA%20targeting%20therapies>
- [6]. Johnson, W., & Pauwels, E. (2017, October). How to optimize human biology: Where genome editing and artificial intelligence collide [pdf] https://www.wilsoncenter.org/sites/default/files/media/documents/publication/how_to_optimize_human_biology.pdf
- [7]. Jordan, M. I., and T. M. Mitchell. "Machine Learning: Trends, Perspectives, and Prospects." *Science* 349.6245 (2015): 255–260. science.sciencemag.org. Web.
- [8]. Ng, D. (2020, June). A brief history of CRISPR-Cas9 genome-editing tools. Retrieved September 2023, from <https://bitesizebio.com/47927/history-crispr/>
- [9]. Zhang, H., Qin, C., An, C. et al. Application of the CRISPR/Cas9-based gene editing technique in basic research, diagnosis, and therapy of cancer. *Mol Cancer* 20, 126 (2021). <https://doi.org/10.1186/s12943-021-01431-6>